Starting with EGFR, treatments have been released. The first dual inhibitor was also released. Non-small cell lung cancer treatment is facing a new turning point with the emergence of various targeted anticancer drugs. Precise treatment began by pioneering areas where there were no treatments, such as KRAS, MET, and EGFR Exon 20.

◆ New KRAS drug in 40 years, 8 global companies will develop

For the first time in 40 years this year, a new drug targeting KRAS mutations has emerged. It is Amgen's Lumakras, approved by the MFDS on the 14th. Lumakras can be used as a secondary treatment for KRAS G12C mutation local progression or metastatic non-small cell lung cancer. Non-small cell lung